Teva TEV-408 protects against gluten-induced intestinal damage in Phase 2a celiac trial
Teva’s TEV-408 met the primary endpoint in a 50-patient Phase 2a celiac disease trial, significantly reducing gluten-induced intestinal damage while also limiting inflammatory-cell increases and gastrointestinal symptoms.